Committed to Discovering, Developing, and Delivering Gene Therapies
At Spark® Therapeutics, we believe gene therapy research has the potential to transform the treatment of hemophilia and we understand the importance of developing gene therapies that meet the needs of the hemophilia community. We also know that keeping informed about gene therapy research and investigational gene therapy clinical trials for hemophilia is empowering. For that purpose, we have created resources to support you, including:
Spark Clinical Trial Information: An overview of Spark’s ongoing clinical studies in hemophilia, including a gene transfer study of investigational SPK-8011 and a dosing-finding study of investigational SPK-8016 to support evaluation in patients with inhibitors to FVIII clotting factor.
Clinical Trial FAQs: A guide containing key questions and answers about participating in a gene therapy clinical trial to help you better understand what to generally expect before, during, and after a gene therapy clinical trial.
HemophiliaForward.com: An educational and informative website about the field of gene therapy and how it is being investigated for use in hemophilia. The website includes videos and gives users the ability to learn at their own pace—from basic to advanced. In addition, there are FAQs about gene therapy clinical trials for hemophilia. These questions were compiled with input from the hemophilia community and are addressed through short animations.
Check out FAQs about investigational gene therapy clinical trials for hemophilia, including an animated video about determining if and when it may be a good time to participate in a clinical trial.
N-HEM-US-420110
